Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.
2.

Experience matters more than specialty for carotid stenting outcomes.

Sgroi MD, Darby GC, Kabutey NK, Barleben AR, Lane JS 3rd, Fujitani RM.

J Vasc Surg. 2015 Apr;61(4):933-8. doi: 10.1016/j.jvs.2014.11.066. Epub 2015 Jan 16.

3.

Oral green tea catechin metabolites are incorporated into human skin and protect against UV radiation-induced cutaneous inflammation in association with reduced production of pro-inflammatory eicosanoid 12-hydroxyeicosatetraenoic acid.

Rhodes LE, Darby G, Massey KA, Clarke KA, Dew TP, Farrar MD, Bennett S, Watson RE, Williamson G, Nicolaou A.

Br J Nutr. 2013 Sep 14;110(5):891-900. doi: 10.1017/S0007114512006071. Epub 2013 Jan 28.

4.

Time-travelling and mind-travelling: examining individual differences in self-projection.

Cullen J, Buda M, Darby G, Simons JS.

Psychiatr Danub. 2011 Sep;23 Suppl 1:S182-6.

PMID:
21894132
5.

Characterization of a neurovirulent aciclovir-resistant variant of herpes simplex virus.

Grey F, Sowa M, Collins P, Fenton RJ, Harris W, Snowden W, Efstathiou S, Darby G.

J Gen Virol. 2003 Jun;84(Pt 6):1403-10.

PMID:
12771407
6.

Phenotypic and genotypic characterization of clinical isolates of herpes simplex virus resistant to aciclovir.

Harris W, Collins P, Fenton RJ, Snowden W, Sowa M, Darby G.

J Gen Virol. 2003 Jun;84(Pt 6):1393-401.

PMID:
12771406
7.

Predicting the emergence of drug-resistant HSV-2: new predictions.

Gershengorn HB, Darby G, Blower SM.

BMC Infect Dis. 2003 Mar 24;3:1.

8.

Apolipoprotein A-I in bile inhibits cholesterol crystallization and modifies transcellular lipid transfer through cultured human gall-bladder epithelial cells.

Secknus R, Darby GH, Chernosky A, Juvonen T, Moore EW, Holzbach RT.

J Gastroenterol Hepatol. 1999 May;14(5):446-56.

PMID:
10355509
9.

Predicting and preventing the emergence of antiviral drug resistance in HSV-2.

Blower SM, Porco TC, Darby G.

Nat Med. 1998 Jun;4(6):673-8.

PMID:
9623975
10.

Survey of resistance of herpes simplex virus to acyclovir in northwest England.

Christophers J, Clayton J, Craske J, Ward R, Collins P, Trowbridge M, Darby G.

Antimicrob Agents Chemother. 1998 Apr;42(4):868-72.

11.

Mutations associated with zidovudine resistance in HIV-1 among recent seroconvertors.

Quigg M, Rebus S, France AJ, McMenamin J, Darby G, Leigh Brown AJ.

AIDS. 1997 May;11(6):835-6. No abstract available.

PMID:
9143628
12.

Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex.

Maschera B, Darby G, PalĂș G, Wright LL, Tisdale M, Myers R, Blair ED, Furfine ES.

J Biol Chem. 1996 Dec 27;271(52):33231-5.

13.
14.

High resolution structures of HIV-1 RT from four RT-inhibitor complexes.

Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, Keeling J, Darby G, Jones Y, Stuart D, et al.

Nat Struct Biol. 1995 Apr;2(4):293-302.

PMID:
7540934
15.

Acyclovir--and beyond.

Darby G.

J Int Med Res. 1994;22 Suppl 1:33A-42A. Review.

PMID:
8063023
16.

Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus.

Purifoy DJ, Beauchamp LM, de Miranda P, Ertl P, Lacey S, Roberts G, Rahim SG, Darby G, Krenitsky TA, Powell KL.

J Med Virol. 1993;Suppl 1:139-45. Review.

PMID:
8245881
17.

The acyclovir legacy: its contribution to antiviral drug discovery.

Darby G.

J Med Virol. 1993;Suppl 1:134-8. Review.

PMID:
8245880
18.

Reverse transcriptase of HIV as a target for anti-viral drugs.

Darby G.

Biochem Soc Trans. 1992 May;20(2):505-8. Review. No abstract available.

PMID:
1383062
19.
20.

The clinical significance of antiviral drug resistance.

Darby G, Larder BA.

Res Virol. 1992 Mar-Apr;143(2):116-20. Review. No abstract available.

PMID:
1594792
21.

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, Lange JM, Goudsmit J, Larder BA.

J Infect Dis. 1992 Jan;165(1):105-10.

PMID:
1370174
22.

Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy.

Boucher CA, Tersmette M, Lange JM, Kellam P, de Goede RE, Mulder JW, Darby G, Goudsmit J, Larder BA.

Lancet. 1990 Sep 8;336(8715):585-90.

PMID:
1975378
23.

The role of herpes simplex virus type 1 thymidine kinase in pathogenesis.

Efstathiou S, Kemp S, Darby G, Minson AC.

J Gen Virol. 1989 Apr;70 ( Pt 4):869-79.

PMID:
2543763
24.

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Larder BA, Darby G, Richman DD.

Science. 1989 Mar 31;243(4899):1731-4.

PMID:
2467383
25.

Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir.

Collins P, Larder BA, Oliver NM, Kemp S, Smith IW, Darby G.

J Gen Virol. 1989 Feb;70 ( Pt 2):375-82.

PMID:
2543743
26.

Structural characterization of HIV reverse transcriptase: a target for the design of specific virus inhibitors.

Tisdale M, Larder BA, Lowe DM, Stammers DK, Purifoy DJ, Ertl P, Bradley C, Kemp S, Darby GK, Powell KL.

J Antimicrob Chemother. 1989 Jan;23 Suppl A:47-54.

PMID:
2469675
27.

HIV-1 reverse transcriptase: crystallization and analysis of domain structure by limited proteolysis.

Lowe DM, Aitken A, Bradley C, Darby GK, Larder BA, Powell KL, Purifoy DJ, Tisdale M, Stammers DK.

Biochemistry. 1988 Dec 13;27(25):8884-9.

PMID:
2466481
29.

Structural studies of the acquired immunodeficiency syndrome virus reverse transcriptase.

Larder BA, Purifoy DJ, Powell KL, Bradley C, Kemp S, Tisdale M, Ertl P, Darby GK, Stammers D.

Am J Med. 1988 Aug 29;85(2A):173-5.

PMID:
2457314
30.

AIDS virus reverse transcriptase defined by high level expression in Escherichia coli.

Larder B, Purifoy D, Powell K, Darby G.

EMBO J. 1987 Oct;6(10):3133-7.

31.

Site-specific mutagenesis of AIDS virus reverse transcriptase.

Larder BA, Purifoy DJ, Powell KL, Darby G.

Nature. 1987 Jun 25-Jul 1;327(6124):716-7.

PMID:
2439916
32.
33.

Related functional domains in virus DNA polymerases.

Larder BA, Kemp SD, Darby G.

EMBO J. 1987 Jan;6(1):169-75.

35.

Restoration of wild-type pathogenicity to an attenuated DNA polymerase mutant of herpes simplex virus type 1.

Larder BA, Lisle JJ, Darby G.

J Gen Virol. 1986 Nov;67 ( Pt 11):2501-6.

PMID:
3023535
36.
38.

Cooperative effects between two acyclovir resistance loci in herpes simplex virus.

Darby G, Churcher MJ, Larder BA.

J Virol. 1984 Jun;50(3):838-46.

39.

Virus drug-resistance: mechanisms and consequences.

Larder BA, Darby G.

Antiviral Res. 1984 Apr;4(1-2):1-42. Review. No abstract available.

PMID:
6331303
40.
42.

Latency and acquired resistance--problems in chemotherapy of herpes infections.

Darby G, Field HJ.

Pharmacol Ther. 1983;23(2):217-51. Review. No abstract available.

PMID:
6322214
43.

Isolation and characterization of acyclovir-resistant strains of herpes simplex virus.

Field HJ, Larder BA, Darby G.

Am J Med. 1982 Jul 20;73(1A):369-71.

PMID:
6285724
45.

Hybridization techniques.

Minson AC, Darby G.

Lab Res Methods Biol Med. 1982;5:185-229. Review. No abstract available.

PMID:
6176828
47.

The sensitivity of acyclovir-resistant mutants of herpes simplex virus to other antiviral drugs.

Field H, McMillan A, Darby G.

J Infect Dis. 1981 Feb;143(2):281-5.

PMID:
6260876
48.

Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance.

Darby G, Field HJ, Salisbury SA.

Nature. 1981 Jan 1;289(5793):81-3.

PMID:
6256650

Supplemental Content

Support Center